Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss

Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies

PNC Financial Services logo
PNC Financial ServicesPNC
$73.15B+10.8%
BK
BKBK
$107.6B+9.7%
American International Group logo
American International GroupAIG
$71.9B+6.0%
State Street logo
State StreetSTT
$71.67B+6.3%
Stifel Financial logo
Stifel FinancialSF
$97.97M+79.1%
Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$226.36B+24.5%

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Halozyme Therapeutics (HALO) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $8.88M in Q1 2026.
How has Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss decreased by 98.4% year-over-year, from $571.61M to $8.88M.
What is the long-term trend for Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Over 3 years (2022 to 2025), Halozyme Therapeutics's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a -58.9% compound annual growth rate (CAGR), from $129.54M to $9M.